DorsaVi Ltd (ASX: DVL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
DorsaVi Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
DorsaVi Ltd (ASX: DVL)
Latest News

Share Market News
Why the Dorsavi (ASX:DVL) share price is flying 22% higher today

Share Market News
Why the Dorsavi share price rocketed 277% higher yesterday
⏸️ Investing
Why these 4 ASX shares have tumbled lower today
⏸️ Investing
Dorsavi Ltd share price jumps 8% on FDA clearance
⏸️ Investing
The Dorsavi Ltd share price just fell 16% to a 52-week low
⏸️ Investing
Why these 4 ASX shares have sunk like stones today
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
⏸️ Investing
Why tech share Dorsavi Ltd surged higher today
⏸️ Investing
ASX 200 soars: 13 shares you should have been watching
⏸️ Investing
Why Dorsavi Ltd is one of 5 shares SINKING today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
5 shares under $5 with massive growth potential
DVL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About DorsaVi Ltd
DorsaVi Ltd is engaged in a distribution of innovative motion analysis technologies. It makes wearable sensors, software, and sophisticated algorithms that measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), ViPerform (Elite Sports), and others. The firm operates in two segments: Clinical and Workplace. Its geographical segments are Australia, Europe, and the United States. The company generates the majority of its revenue from Clinical segment.
DVL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Dec 2023 | $0.01 | $0.00 | 0.00% | 50,000 | $0.01 | $0.01 | $0.01 |
07 Dec 2023 | $0.01 | $0.00 | 0.00% | 7,700 | $0.01 | $0.01 | $0.01 |
06 Dec 2023 | $0.01 | $0.00 | 0.00% | 38,471 | $0.01 | $0.01 | $0.01 |
04 Dec 2023 | $0.01 | $0.00 | 0.00% | 19,014 | $0.01 | $0.01 | $0.01 |
29 Nov 2023 | $0.01 | $0.00 | 0.00% | 34,113 | $0.01 | $0.01 | $0.01 |
24 Nov 2023 | $0.01 | $0.00 | 0.00% | 100,000 | $0.01 | $0.01 | $0.01 |
20 Nov 2023 | $0.01 | $0.00 | 0.00% | 146,196 | $0.01 | $0.01 | $0.01 |
17 Nov 2023 | $0.01 | $0.00 | 0.00% | 13,000 | $0.01 | $0.01 | $0.01 |
15 Nov 2023 | $0.01 | $0.00 | 0.00% | 1,595,174 | $0.01 | $0.01 | $0.01 |
13 Nov 2023 | $0.01 | $0.00 | 0.00% | 506,748 | $0.01 | $0.01 | $0.01 |
09 Nov 2023 | $0.01 | $0.00 | 0.00% | 1,148,743 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
06 Oct 2023 | Michael Panaccio | Issued | 1,000,001 | $11,000 |
Issue of options.
|
06 Oct 2023 | Caroline Elliott | Issued | 1,000,001 | $11,000 |
Issue of options.
|
06 Oct 2023 | Ashraf Attia | Issued | 1,000,001 | $11,000 |
Issue of options.
|
03 Jul 2023 | Michael Panaccio | Issued | 1,000,001 | $11,000 |
Issue of options.
|
03 Jul 2023 | Caroline Elliott | Issued | 1,000,001 | $11,000 |
Issue of options.
|
03 Jul 2023 | Andrew Ronchi | Issued | 3,450,705 | $43,000 |
Director remuneration.
|
03 Jul 2023 | Andrew Ronchi | Transfer | 3,700,000 | $48,100 |
Off-market transfer.
|
03 Jul 2023 | Andrew Ronchi | Transfer | 3,700,000 | $48,100 |
Off-market transfer.
|
03 Jul 2023 | Ashraf Attia | Issued | 1,000,001 | $11,000 |
Issue of options.
|
03 Apr 2023 | Michael Panaccio | Issued | 733,334 | $1,100 |
Issue of options.
|
03 Apr 2023 | Caroline Elliott | Issued | 733,334 | $1,100 |
Issue of options.
|
03 Apr 2023 | Ashraf Attia | Issued | 733,334 | $1,100 |
Issue of options.
|
03 Jan 2023 | Michael Panaccio | Issued | 916,668 | $1,100 |
Issue of options.
|
03 Jan 2023 | Caroline Elliott | Issued | 916,668 | $1,100 |
Issue of options.
|
03 Jan 2023 | Ashraf Attia | Issued | 916,668 | $1,100 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael Panaccio | Non-Executive Director | May 2008 |
Mr Panaccio is one of the founding directors of Starfish Ventures Pty Ltd. He was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to joining JAFCO, Michael was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. Michael has previously been a director of technology businesses in Australia and the US including ImpediMed Ltd, SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. He is Member of Risk Committee.
|
Ms Caroline Ann Elliott | Non-Executive Director | Nov 2017 |
Ms Elliott is currently a Director of the National Film and Sound Archive of Australia, St John's Ambulance Australia (Vic) and Wiltrust Nominees Pty Ltd. She has previously held non-executive director roles at Cell Therapies Pty Ltd, Peter MacCallum Cancer Centre and the Public Transport Ombudsman Limited. She is currently the Chief Executive Officer at apparel business, The Propel Group Pty Ltd, and was previously the CFO and Company Secretary at Optal Ltd. She is Chair of Risk Committee.
|
Dr Andrew James Ronchi | Chief Executive OfficerExecutive Director | Feb 2008 |
Dr Ronchi was a practising physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centres, the largest of these employing 28 staff (including 13 physiotherapists).
|
Mr Ashraf Attia | Non-Executive Director | Jul 2008 |
Mr Attia has had senior management experience in multinational operations for over 30 years within the medical devices, biotechnology and diagnostics industries. He is currently Chief Executive Officer of Bionic Vision Technologies. Prior to Bionic Vision, Ash held the position of Vice President of Asia Pacific, Middle East and Israel at TransMedics Inc. He has held several senior executive roles with global medical devices organizations and has experience in the areas of commercialization, business development, clinical, regulatory, R&D, strategic marketing, sales and distribution management. He is Member of Risk Committee.
|
Dr Michael Winlo | Non-Executive Director | Oct 2023 |
Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR).
|
Mr Justin Mouchacca | Company Secretary | Sep 2023 |
-
|
Justin Mouchacca | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Mr Bilal Ahmad | 53,100,000 | 9.54% |
Starfish Technology Fund Ii Nominees A Pty Ltd | 48,763,230 | 8.76% |
Starfish Technology Fund Ii Nominees B Pty Ltd | 48,763,229 | 8.76% |
Mr Sufian Ahmad <Sixty Two Capital A/C> | 20,000,000 | 3.59% |
Ms Chunyan Niu | 19,382,316 | 3.48% |
Mr Bin Liu | 18,181,818 | 3.27% |
Vesparum Group Investments Pty Ltd | 17,182,142 | 3.09% |
Mr Sufian Ahmad | 17,100,000 | 3.07% |
Kobala Investments Pty Ltd <Fernando Edward Family A/C> | 15,000,000 | 2.69% |
Tanarny Super Fund Pty Ltd <Tanarny Super Fund A/C> | 14,209,132 | 2.55% |
Ddpevcic (Wa) Pty Ltd <Dominic Family A/C> | 12,590,909 | 2.26% |
Clayton Capital Pty Ltd | 12,590,909 | 2.26% |
449 Investments Pty Ltd <The A&R Hynes Family S/F A/C> | 10,429,167 | 1.87% |
Mr Salvatore Di Vincenzo | 8,517,332 | 1.53% |
Glenbarry Pty Ltd <Thomas A Hutchins Family A/C> | 8,333,333 | 1.50% |
Ar Bsm Pty Ltd <Ar Bsm A/C> | 7,606,965 | 1.37% |
Valence Holdings Pty Ltd The Pw & Cm Stinton <Superannuation Fund A/C> | 5,688,006 | 1.02% |
Mr Brendan Thomas Case | 5,060,240 | 0.91% |
Dr Zonair Ikram | 4,534,722 | 0.81% |
Creative Hindsight Pty Ltd | 4,244,417 | 0.76% |